207 related articles for article (PubMed ID: 37941440)
1. Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease.
Kaminski TW; Katoch O; Li Z; Hanway CB; Dubey RK; Alagbe A; Brzoska T; Zhang H; Sundd P; Kato GJ; Novelli EM; Pradhan-Sundd T
Haematologica; 2024 May; 109(5):1535-1550. PubMed ID: 37941440
[TBL] [Abstract][Full Text] [Related]
2. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V
Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304
[TBL] [Abstract][Full Text] [Related]
3. P-selectin deficiency promotes liver senescence in sickle cell disease mice.
Vats R; Kaminski TW; Ju EM; Brozska T; Tutuncuoglu E; Tejero J; Novelli EM; Sundd P; Pradhan-Sundd T
Blood; 2021 May; 137(19):2676-2680. PubMed ID: 33619560
[TBL] [Abstract][Full Text] [Related]
4. Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease.
Vats R; Liu S; Zhu J; Mukhi D; Tutuncuoglu E; Cardenes N; Singh S; Brzoska T; Kosar K; Bamne M; Jonassaint J; Adebayo Michael A; Watkins SC; Hillery C; Ma X; Nejak-Bowen K; Rojas M; Gladwin MT; Kato GJ; Ramakrishnan S; Sundd P; Monga SP; Pradhan-Sundd T
Hepatology; 2020 Dec; 72(6):2165-2181. PubMed ID: 32190913
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.
Keleku-Lukwete N; Suzuki M; Panda H; Otsuki A; Katsuoka F; Saito R; Saigusa D; Uruno A; Yamamoto M
Blood Adv; 2019 Apr; 3(8):1285-1297. PubMed ID: 31015205
[TBL] [Abstract][Full Text] [Related]
6. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
Nader E; Romana M; Connes P
Front Immunol; 2020; 11():454. PubMed ID: 32231672
[TBL] [Abstract][Full Text] [Related]
7. Vascular pathophysiology of sickle cell disease.
Connes P; Renoux C; Joly P; Nader E
Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.
Pradhan-Sundd T; Kato GJ; Novelli EM
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C494-C504. PubMed ID: 35759437
[TBL] [Abstract][Full Text] [Related]
9. HO-1
Liu Y; Jing F; Yi W; Mendelson A; Shi P; Walsh R; Friedman DF; Minniti C; Manwani D; Chou ST; Yazdanbakhsh K
Blood; 2018 Apr; 131(14):1600-1610. PubMed ID: 29437594
[TBL] [Abstract][Full Text] [Related]
10. Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.
Abdulmalik O; Darwish NHE; Muralidharan-Chari V; Taleb MA; Mousa SA
Haematologica; 2022 Feb; 107(2):532-540. PubMed ID: 33567814
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.
Alramadhani D; Aljahdali AS; Abdulmalik O; Pierce BD; Safo MK
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806451
[TBL] [Abstract][Full Text] [Related]
12. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
[TBL] [Abstract][Full Text] [Related]
13. Sickle cell disease, vasculopathy, and therapeutics.
Kassim AA; DeBaun MR
Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological characterization of the Townes mouse model for sickle cell disease.
Alvarez-Argote J; Dlugi TA; Sundararajan T; Kleynerman A; Faber ML; McKillop WM; Medin JA
Transl Res; 2023 Apr; 254():77-91. PubMed ID: 36323381
[TBL] [Abstract][Full Text] [Related]
15. Sickle cell diseases: What can nuclear medicine offer?
Niccoli Asabella A; Altini C; Nappi AG; Lavelli V; Ferrari C; Marzullo A; Loiodice A; Rubini G
Hell J Nucl Med; 2019; 22(1):2-3. PubMed ID: 30843001
[TBL] [Abstract][Full Text] [Related]
16. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
Nader E; Conran N; Romana M; Connes P
Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of Sickle Cell Disease.
Sundd P; Gladwin MT; Novelli EM
Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
[TBL] [Abstract][Full Text] [Related]
18. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease.
Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM
Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790
[TBL] [Abstract][Full Text] [Related]
19. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
[TBL] [Abstract][Full Text] [Related]
20. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
